Highlights Pharming Group N.V.

Equities

PHARM

NL0010391025

Market Closed - Euronext Amsterdam Other stock markets 11:35:07 2024-05-17 am EDT			5-day change	1st Jan Change
0.845 ^EUR	-1.63%		-3.21%	-18.04%

May. 08	Transcript : Pharming Group N.V., Q1 2024 Earnings Call, May 08, 2024
May. 08	Pharming Group N.V. Provides Revenue Guidance for 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pharming Group N.V. Provides Revenue Guidance for 2024	May. 08	CI
Pharming Group N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Pharming Group to Buy Back EUR123 Million of Bonds due 2025	Apr. 22	MT
Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds	Apr. 18	MT
Pharming Group N.V. Announces Completion of Enrollment in Pediatric Clinical Trial of Leniolisib	Apr. 08	CI
Pharming Group Finishes Enrolling Patients for Phase 3 Pediatric Testing of its Treatment for Rare Auto-Immune Disorder	Apr. 08	MT
Pharming Group N.V. Provides Earnings Guidance for the Year 2024	Mar. 14	CI
Pharming Group Seeks Acquisitions	Mar. 14	CI
Pharming Group N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Pharming Group N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Pharming Group Announces Development Plans for Leniolisib for Additional Primary Immunodeficiencies	Dec. 15	CI
Pharming Group Expects EU Panel Opinion in 2024 for Rare Immunodeficiency Treatment	Nov. 10	MT
Pharming Group N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan	23-08-09	CI
Pharming Seeks Acquisitions	23-08-03	CI
Pharming Group N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-03	CI
Pharming Group to Sell Rare Pediatric Disease Priority Review Voucher to Novartis for About $21.1 Million	23-06-01	MT
Pharming Group Swings to Q1 Loss, Revenue Declines	23-05-11	MT
Pharming Group N.V. Reports Earnings Results for the First Quarter Ended March 16, 2023	23-05-11	CI
Pharming Group N.V. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pharming Group N.V.

Equities

PHARM

NL0010391025

Highlights

Filters